Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
Penny Whiting,Penny Whiting,Robert Wolff,Sohan Deshpande,Marcello Di Nisio,Steven Duffy,Adrian V. Hernandez,Adrian V. Hernandez,J. Christiaan Keurentjes,Shona H. Lang,Kate Misso,Steve Ryder,Simone Schmidlkofer,Marie Westwood,Jos Kleijnen +14 more
Reads0
Chats0
TLDR
There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.Abstract:
Importance Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. Objective To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. Data Sources Twenty-eight databases from inception to April 2015. Study Selection Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. Data Extraction and Synthesis Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis. Main Outcomes and Measures Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs. Results A total of 79 trials (6462 participants) were included; 4 were judged at low risk of bias. Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], −0.46 [95% CI, −0.80 to −0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, −0.12 [95% CI, −0.24 to 0.01]; 5 trials). There was an increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. Conclusions and Relevance There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.read more
Citations
More filters
Journal ArticleDOI
Variation in cannabis potency and prices in a newly legal market: Evidence from 30 million cannabis sales in Washington state.
Rosanna Smart,Jonathan P. Caulkins,Jonathan P. Caulkins,Beau Kilmer,Steven Davenport,Gregory Midgette +5 more
TL;DR: In this paper, the authors assess trends and variation in the market share of product types and potency sold in a legal cannabis retail market, and estimate how potency and purchase quantity influence price variation for cannabis flower.
Journal ArticleDOI
Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review
Cecilia Sorensen,Kristen DeSanto,Laura M. Borgelt,Kristina T. Phillips,Andrew A. Monte,Andrew A. Monte +5 more
TL;DR: Cannabinoid hyperemesis syndrome is a cyclic vomiting syndrome, preceded by daily to weekly cannabis use, usually accompanied by symptom improvement with hot bathing, and resolution with cessation of cannabis, which appears to be the best treatment.
Journal ArticleDOI
The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review
Shannon M. Nugent,Benjamin J. Morasco,Maya E O'Neil,Michele Freeman,Allison Low,Karli Kondo,Camille Elven,Bernadette Zakher,Makalapua Motu'apuaka,Robin Paynter,Devan Kansagara +10 more
TL;DR: The objectives of this systematic review were to assess the efficacy of cannabis for treating chronic pain and to provide a broad overview of the short- and long-term physical and mental health effects of cannabis use in Chronic pain and general patient populations.
Journal ArticleDOI
Gilles de la Tourette syndrome
Mary M. Robertson,Valsamma Eapen,Valsamma Eapen,Harvey S. Singer,Davide Martino,Jeremiah M. Scharf,Jeremiah M. Scharf,Peristera Paschou,Peristera Paschou,Veit Roessner,Douglas W. Woods,Marwan Hariz,Marwan Hariz,Carol A. Mathews,Rudi Črnčec,Rudi Črnčec,James F. Leckman +16 more
TL;DR: Gilles de la Tourette syndrome (GTS) is a childhood-onset neurodevelopmental disorder characterized by several motor and phonic tics as discussed by the authors, which usually develops before 10 years of age, exhibit a waxing and waning course and typically improve with increasing age.
Journal ArticleDOI
The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Gin S Malhi,Gin S Malhi,Erica Bell,Erica Bell,Darryl Bassett,Philip Boyce,Philip Boyce,Richard A. Bryant,Philip Hazell,Malcolm Hopwood,Bill Lyndon,Roger T. Mulder,Richard J Porter,Ajeet B. Singh,Greg Murray +14 more
TL;DR: In this article, the authors provide advice and guidance regarding the management of mood disorders, derived from scientific evidence and supplemented by expert clinical consensus to formulate s that maximise the quality of care.
References
More filters
Journal ArticleDOI
Meta-Analysis in Clinical Trials*
TL;DR: This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Journal ArticleDOI
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
Julian P T Higgins,Douglas G. Altman,Peter C Gøtzsche,Peter Jüni,David Moher,Andrew D Oxman,Jelena Savović,Kenneth F. Schulz,Laura Weeks,Jonathan A C Sterne +9 more
TL;DR: The Cochrane Collaboration’s tool for assessing risk of bias aims to make the process clearer and more accurate.
Book
Cochrane Handbook for Systematic Reviews of Interventions
Julian P T Higgins,Sally Green +1 more
TL;DR: The Cochrane Handbook for Systematic Reviews of Interventions is the official document that describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions.